Equities Analysts Offer Predictions for Liquidia Q3 Earnings

Liquidia Corporation (NASDAQ:LQDA) – HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Liquidia in a research note issued on Thursday, August 13th. HC Wainwright analyst A. Fein now anticipates that the company will earn $1.01 per share for the quarter, down from their prior forecast of $1.15. The consensus estimate for Liquidia’s current full-year earnings is $3.02 per share.

Other equities analysts have also issued reports about the stock. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Lifesci Capital reissued a “market perform” rating and set a $90.00 price objective on shares of Liquidia in a report on Wednesday. Bank of America upped their target price on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday. Stephens set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and a consensus price target of $98.08.

Liquidia Stock Down 8.5%

Shares of LQDA stock opened at $72.10 on Friday. The stock’s fifty day moving average price is $78.42 and its 200 day moving average price is $55.00. Liquidia has a 1-year low of $21.15 and a 1-year high of $93.61. The company has a market cap of $6.41 billion, a price-to-earnings ratio of 52.63 and a beta of 0.58. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 237.10%. The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter in the prior year, the business posted ($0.49) earnings per share. The firm’s quarterly revenue was up 1842.1% on a year-over-year basis.

Insider Buying and Selling

In other Liquidia news, CAO Dana Boyle sold 1,600 shares of the stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $140,048.00. Following the sale, the chief accounting officer directly owned 167,919 shares of the company’s stock, valued at approximately $14,697,950.07. This trade represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,185 shares of Liquidia stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $84,739.35. Following the transaction, the insider owned 65,947 shares of the company’s stock, valued at $4,715,869.97. The trade was a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,756,861 shares of company stock valued at $122,981,112 in the last 90 days. 25.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia in the 4th quarter worth approximately $25,000. NewEdge Advisors LLC acquired a new position in Liquidia during the second quarter worth $25,000. Covestor Ltd lifted its holdings in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after purchasing an additional 4,927 shares during the period. Finally, Globeflex Capital L P purchased a new stake in shares of Liquidia during the second quarter worth about $175,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove a sharp increase in revenue and profitability. Liquidia reported approximately $171.7 million in quarterly revenue, including about $170.4 million from YUTREPIA, while net income reached roughly $74.7 million. Management also reaffirmed its goal of generating more than $1 billion in net revenue in 2027. LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
• Positive Sentiment: Analysts raised their targets following the earnings report. Needham increased its target to $110 from $70 and maintained a buy rating, while BTIG raised its target to $111 from $109 and reiterated buy. Bank of America lifted its target to $92 from $79, although it retained a neutral rating. Liquidia Stock Price Expected to Rise, Needham Analyst Says
• Neutral Sentiment: Lifesci Capital reaffirmed a market perform rating but set a $90 price target, indicating potential upside while signaling a more cautious view than the buy-rated analysts. Liquidia Earns Market Perform Rating from Lifesci Capital
• Negative Sentiment: Adjusted earnings per share of $0.74 were slightly below the company’s reported consensus estimate of $0.76, even though revenue exceeded expectations. The modest earnings miss, elevated expectations after a 155% year-to-date rally, and anticipated higher second-half research and development spending for the L606 Phase 3 program contributed to the selloff and a gap lower in the shares. Liquidia Shares Gap Down on Disappointing Earnings

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).